tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Perseus Proteomics Updates PPMX-T003 Project Details

Story Highlights
Perseus Proteomics Updates PPMX-T003 Project Details

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Perseus Proteomics, Inc. ( (JP:4882) ) just unveiled an announcement.

Perseus Proteomics Inc. has announced an amendment regarding its PPMX-T003 project, which is part of a drug discovery support program for orphan drugs. The amendment clarifies that the research group led by Dr. Ai Kotani at Osaka University, rather than Osaka Metropolitan University, has identified PPMX-T003 as a potential therapeutic drug for ANKL. This correction may impact stakeholders’ understanding of the project’s progress and the company’s collaboration with academic institutions.

More about Perseus Proteomics, Inc.

YTD Price Performance: 16.37%

Average Trading Volume: 792,805

Technical Sentiment Consensus Rating: Sell

Current Market Cap: Yen9.64B

Learn more about 4882 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1